Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Portal vein embolization followed by camrelizumab plus capecitabine neoadjuvant therapy before radical resection for hilar cholangiocarcinoma
ChiCTR2000036879Phase 4Not yet recruiting
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
- Start
- Oct 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of camrelizumab and capecitabine in hilar cholangiocarcinoma (HC), sponsored by Eastern Hepatobiliary Surgery Hospital. Primary endpoints: Safety, Objective response rate and 3 more. Planned start Oct 2020; status: not yet recruiting.
02
Drugs
camrelizumabcapecitabine
03
Conditions
hilar cholangiocarcinoma (HC)
Beyond the preview
Go deeper on ChiCTR2000036879.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000036879.